Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05066217 · ClinicalTrials.gov registry record · Phase 3

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

A Phase 3 study of Lennox Gastaut Syndrome, sponsored by Epygenix.

Recruiting
Registry status
Phase 3
Development phase
260
Enrollment target
4
Study locations

NCT05066217: Recruiting Phase 3 study of Lennox Gastaut Syndrome, sponsored by Epygenix.

NCT05066217 is a Phase 3 study of Lennox Gastaut Syndrome that is actively recruiting participants, run by Epygenix. The registered enrollment target is 260 participants, below the 581-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (55% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05066217, a Phase 3 study of Lennox Gastaut Syndrome, is actively recruiting participants, sponsored by Epygenix.

RECRUITING
Registry status
Phase 3
Development phase
260 participants
Enrollment target
4
Study locations

Study Summary

This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).

Primary Outcome

Percent change in CMMS-28 from the Baseline Period through the end of the DB Period

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Clemizole HCl

Study Locations (4)

Florida

  • Rare Disease Research - Kissimmee

Minnesota

  • Minnesota Epilepsy Group, P.A. - Roseville

New Jersey

  • Neurology Center for Epilepsy and Seizures - Marlboro

North Carolina

  • On-Site Clinical Solution - Charlotte

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2025-04-09
Est. Completion 2029-11-01
Phase Phase 3
Epygenix

3 total trials

What NCT05066217 shows while recruiting

NCT05066217 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 581-participant average among 10 other Lennox Gastaut Syndrome trials with a reported enrollment target (55% lower).

The record links to 1 condition, with Lennox Gastaut Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05066217 reports a single indexed study location in Florida, Minnesota, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05066217 about?

NCT05066217 is a clinical study titled "An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome". This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).

What is the current status of trial NCT05066217?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2025-04-09. Estimated completion is 2029-11-01.

What conditions does trial NCT05066217 study?

This clinical trial studies the following conditions: Lennox Gastaut Syndrome.

What interventions are being tested in trial NCT05066217?

The interventions under investigation include: Placebo (DRUG), Clemizole HCl (DRUG).

Who is sponsoring clinical trial NCT05066217?

This trial is sponsored by Epygenix, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05066217 being conducted?

This trial has 4 study locations across Florida, Minnesota, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lennox Gastaut Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05066217's enrollment target sits among peer trials

260 3rd of 10 higher than 8 of 10 other Lennox Gastaut Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lennox Gastaut Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02283996 · 260 participants · Phase 4

    Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

  • NCT03276793 · 260 participants · NA

    Brain Connectivity in Depression

  • NCT03407469 · 260 participants

    Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

  • NCT03713125 · 260 participants · NA

    Executive Function in Early Childhood

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05066217, the US trial registry maintained by the National Library of Medicine. NCT05066217 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.